Inhibrx Biosciences (INBX) - צמיחת רווחי EPS רבעונית
Inhibrx Biosciences (INBX) business is shielded from macroeconomic downturns, as demand for oncology drugs remains stable. However, stringent FDA oversight and costly clinical trials create significant barriers to entry. This quarterly EPS chart, where the -8.20 parameter determines the metric's value, confirms a high level of scientific confidence in the company's assets among major institutional investors.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%9E%D7%A9%D7%A0%D7%94%20%D7%9C%D7%A9%D7%A0%D7%94%20%D7%91-12%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_INBX_-_Inhibrx-Biosciences_-_Year-over-year-net-earnings-per-share-growth-for-the-last-12-months "צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים Inhibrx Biosciences Inc (INBX): לתקופה 04.07.2022 - 15.11.2026 | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת Inhibrx Biosciences
An issuer's long-term reliability is determined by the stability of its earnings per share generation. This indicator tracks the daily dynamics of quarterly EPS changes, excluding temporary data gaps. By analyzing the quarterly growth slice of EPS, an investor sees the current value of -8.20, which allows for the timely recognition of a value trap. For Inhibrx Biosciences (INBX), given its lack of commercial products, such volatility confirms a dependence on external financing.
